14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
KYMR vs CRSP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). KYMR carries a Unified Composite Score of 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin).
Growth vs. Quality Trade-Off: KYMR earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. CRSP 44.7/100 HOLD) and 1.04β · 54% Vol risk profile, whereas CRSP leads top-line expansion (+1325.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KYMR vs CRSP Key Questions & Quantitative Answers
As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). KYMR carries a Unified Composite Score of 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Growth vs. Quality Trade-Off: KYMR earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. CRSP 44.7/100 HOLD) and 1.04β · 54% Vol risk profile, whereas CRSP leads top-line expansion (+1325.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KYMR leads the Growth & Scale pillar: KYMR posts +466.4% YoY revenue growth and +0.0% YoY earnings growth on $102M TTM revenue (N/A gross margin, -396.0% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), KYMR cumulative revenue shifted +33.3% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, KYMR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.
CRSP screens cheaper on headline valuation multiples. KYMR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.3x EV/Revenue (unreported FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KYMR (-27.3% ROE) versus CRSP (-25.6% ROE) capital efficiency.
In options market volatility and institutional positioning, KYMR carries 129.6% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 54% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.